Preclinical assessment of drug–drug interaction of fb‐PMT, a novel anti‐cancer thyrointegrin αvβ3 an...
Preclinical assessment of drug–drug interaction of fb‐PMT, a novel anti‐cancer thyrointegrin αvβ3 antagonist
About this item
Full title
Author / Creator
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
The objective of the current study was to identify potential drug–drug interactions (DDIs) with the drug candidate fb‐PMT, a novel anticancer thyrointegrin αvß3 antagonist. This was accomplished by using several in vitro assays to study interactions of fb‐PMT with both cytochrome P450 (CYP) enzymes and drug transporters, two common mechanisms leadi...
Alternative Titles
Full title
Preclinical assessment of drug–drug interaction of fb‐PMT, a novel anti‐cancer thyrointegrin αvβ3 antagonist
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_442f979fd53f48b787fe4e6b8a1cad97
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_442f979fd53f48b787fe4e6b8a1cad97
Other Identifiers
ISSN
1752-8054
E-ISSN
1752-8062
DOI
10.1111/cts.13504
